查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576842

Gliclazide市場：按藥物類型、劑型、包裝、分銷管道、患者年齡層、最終用戶、應用分類 - 2025-2030 年全球預測

Gliclazide Market by Drug Type (Immediate Release Gliclazide, Modified Release Gliclazide), Formulation (Capsules, Tablets), Dosage Form, Packaging, Distribution Channel, Patient Age Group, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年Gliclazide市值為137.2億美元，預計2024年將達到146.4億美元，複合年成長率為7.21%，預計到2030年將達到223.5億美元。

Gliclazide是一種口服降血糖Sulfonylurea，用於透過刺激胰臟BETA細胞分泌胰島素來治療第二型糖尿病。這種需求是由於糖尿病盛行率不斷增加，需要有效的血糖控制方案來預防併發症。Gliclazide適應症廣泛，主要針對中老年第2型糖尿病患者，常與飲食、運動療法等生活方式介入結合使用。最終用途範圍主要包括可以很好地管理處方和監測的醫院、診所和門診病人場所。Gliclazide市場的開拓是由糖尿病盛行率上升、認知提高以及對有效且負擔得起的糖尿病管理的需求所推動的，特別是在糖尿病負擔日益增加的新興市場。機會在於擴大新興市場的可及性、利用數位健康平台進行監測以及整合多學科方法進行糖尿病護理，包括Gliclazide。然而，低血糖等潛在副作用、新型糖尿病藥物的競爭以及患者依從性的需求等挑戰可能會阻礙成長。限制也來自於精確劑量個體化的需要，這可能使治療方法變得複雜。患者教育、聯合治療和個人化醫療等領域的創新可能會進一步推動市場滲透。長期給藥（例如緩釋性）和新型遞送系統的研究可能會改善治療結果。了解市場動態突顯了競爭格局，需要專注於成本效益、監管挑戰以及適應快速的技術進步。為了利用市場機會，公司應該投資新配方的研發，透過策略夥伴關係增加市場佔有率，並將行銷力度集中在糖尿病人口快速成長的新興國家。

主要市場統計
基準年[2023] 137.2億美元
預測年份 [2024] 146.4億美元
預測年份 [2030] 223.5億美元
複合年成長率（%） 7.21%

市場動態：揭示快速發展的Gliclazide市場的關鍵市場洞察

供需的動態交互作用正在改變Gliclazide市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 由於不健康的飲食和久坐的生活方式，肥胖人口不斷增加
    • 增加對醫療衛生基礎設施和醫療設施的投資
  • 市場限制因素
    • 市面上替代療法的可用性
  • 市場機會
    • 增加研發和醫療基礎建設的投資
    • 糖尿病治療藥物個別化的進展
  • 市場挑戰
    • 嚴格的法規環境導致核准流程冗長

波特五力：駕馭Gliclazide市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解Gliclazide市場的外部影響

外部宏觀環境因素對Gliclazide市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解Gliclazide市場競爭狀況

對Gliclazide市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的見解，以應對日益激烈的競爭。

FPNV 定位矩陣Gliclazide市場供應商的績效評估

FPNV定位矩陣是評估Gliclazide市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了Gliclazide市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，Gliclazide市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 不健康的飲食習慣和久坐的生活方式相結合導致肥胖人數的增加。
      • 增加對醫療衛生基礎設施和醫療設施的投資
    • 抑制因素
      • 市面上替代治療方法的可用性
    • 機會
      • 增加研發和醫療基礎建設的投資
      • 糖尿病藥物個體化的進展
    • 任務
      • 嚴格的法規環境減緩了核准流程
  • 市場區隔分析
    • 藥物類型：由於血糖控制時間更長且更一致，因此擴大採用緩釋性藥物Gliclazide
    • 最終用戶：有效管理急性病例的快速反應提高了醫院的採用率
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章Gliclazide市場藥物按類型

  • 即時釋Gliclazide
  • 改良釋放Gliclazide

第7章Gliclazide處方市場

  • 膠囊
  • 藥片

第8章Gliclazide劑型市場

  • 聯合治療
  • 單一療法

第9章Gliclazide市場：依包裝分類

  • 泡殼包裝
  • 瓶子
  • 小袋

第10章Gliclazide市場：按分銷管道

  • 藥局
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章按患者年齡層別分類的Gliclazide市場

  • 成人用
  • 老年病
  • 小兒科

第12章Gliclazide市場：依最終用戶分類

  • 居家護理
  • 醫院
  • 專科診所

第13章Gliclazide市場：依應用分類

  • 血糖控制
  • 對心血管的好處
  • 改善胰島素敏感性

第14章Gliclazide美洲市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第15章 亞太地區Gliclazide市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第16章 歐洲、中東和非洲Gliclazide市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第17章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Endogenex 已獲得 8,800 萬美元的 C 系列資金籌措，以推進創新 2 型糖尿病治療的重要 ReCET 研究。
  • 戰略分析和建議
Product Code: MRR-81515600A44D

The Gliclazide Market was valued at USD 13.72 billion in 2023, expected to reach USD 14.64 billion in 2024, and is projected to grow at a CAGR of 7.21%, to USD 22.35 billion by 2030.

Gliclazide is an oral hypoglycemic sulfonylurea class medication used to manage type 2 diabetes by stimulating insulin secretion from pancreatic beta cells. Its necessity stems from the growing prevalence of diabetes, which calls for effective glycemic control options to prevent complications. The application of gliclazide extends to a wide demographic, primarily targeting middle-aged and elderly individuals with type 2 diabetes, and is often combined with lifestyle interventions like diet and exercise. The end-use scope predominantly involves hospitals, clinics, and outpatient care settings, where prescription and monitoring can be adequately managed. Market growth for gliclazide is driven by rising diabetes prevalence, increased awareness, and the demand for effective and affordable diabetes management, especially in developing regions where the burden of diabetes is increasing. Opportunities lie in expanding accessibility in emerging markets, leveraging digital health platforms for monitoring, and integrating multi-disciplinary approaches to diabetes care that include gliclazide. However, challenges such as potential side effects like hypoglycemia, competition from newer classes of diabetes medications, and the necessity of patient compliance can hinder growth. Limitations also arise from the requirement of precise dosage personalizations, which can complicate treatment regimens. Innovating in areas such as patient education, combination therapies, and personalized medicine can propel further market penetration. Research into prolonged or novel delivery systems, like controlled-release formulations, could enhance therapeutic outcomes. Understanding the market dynamics highlights a competitive landscape, with a need to focus on cost-effectiveness, regulatory challenges, and adaptation to rapid technological advancements. To capitalize on market opportunities, companies should invest in R&D for novel formulations, enhance market presence through strategic partnerships, and emphasize marketing efforts on emerging economies with burgeoning diabetic populations.

KEY MARKET STATISTICS
Base Year [2023] USD 13.72 billion
Estimated Year [2024] USD 14.64 billion
Forecast Year [2030] USD 22.35 billion
CAGR (%) 7.21%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gliclazide Market

The Gliclazide Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing obese population coupled with unhealthy diets and sedentary lifestyles
    • Rising investments in healthcare infrastructure and medical facilities
  • Market Restraints
    • Availability of alternative treatments in the market
  • Market Opportunities
    • Rising investment in R&D and healthcare infrastructure development
    • Advancements in personalize diabetic medications
  • Market Challenges
    • Stringent regulatory environment leading to time-consuming approval process

Porter's Five Forces: A Strategic Tool for Navigating the Gliclazide Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gliclazide Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gliclazide Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gliclazide Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gliclazide Market

A detailed market share analysis in the Gliclazide Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gliclazide Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gliclazide Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gliclazide Market

A strategic analysis of the Gliclazide Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gliclazide Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., Biocon, Cipla, Dr. Reddy's Laboratories, Kavya Pharma, Kreative Organics, Lexicare Pharma Private Limited, Lupin Pharmaceuticals, Mankind Pharma, MANUS AKTTEVA BIOPHARMA LLP, Sanify Healthcare, Shobha Life Sciences, Supra Chemicals, Torrent Pharmaceuticals, Wellona Pharma, and Zeelab Pharmacy Private Limited.

Market Segmentation & Coverage

This research report categorizes the Gliclazide Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Immediate Release Gliclazide and Modified Release Gliclazide.
  • Based on Formulation, market is studied across Capsules and Tablets.
  • Based on Dosage Form, market is studied across Combination Therapy and Monotherapy.
  • Based on Packaging, market is studied across Blister Packs, Bottles, and Pouches.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Application, market is studied across Blood Sugar Control, Cardiovascular Benefits, and Insulin Sensitivity Improvement.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing obese population coupled with unhealthy diets and sedentary lifestyles
      • 5.1.1.2. Rising investments in healthcare infrastructure and medical facilities
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative treatments in the market
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investment in R&D and healthcare infrastructure development
      • 5.1.3.2. Advancements in personalize diabetic medications
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment leading to time-consuming approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug type: Increasing adoption of modified release gliclazide due to more extended and consistent blood glucose control
    • 5.2.2. End-User: Increasing adoption in hospitals due to rapid onset of action to manage acute cases effectively
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gliclazide Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Immediate Release Gliclazide
  • 6.3. Modified Release Gliclazide

7. Gliclazide Market, by Formulation

  • 7.1. Introduction
  • 7.2. Capsules
  • 7.3. Tablets

8. Gliclazide Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Combination Therapy
  • 8.3. Monotherapy

9. Gliclazide Market, by Packaging

  • 9.1. Introduction
  • 9.2. Blister Packs
  • 9.3. Bottles
  • 9.4. Pouches

10. Gliclazide Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Drug Stores
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. Retail Pharmacies

11. Gliclazide Market, by Patient Age Group

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Geriatric
  • 11.4. Pediatric

12. Gliclazide Market, by End-User

  • 12.1. Introduction
  • 12.2. Homecare
  • 12.3. Hospitals
  • 12.4. Specialty Clinics

13. Gliclazide Market, by Application

  • 13.1. Introduction
  • 13.2. Blood Sugar Control
  • 13.3. Cardiovascular Benefits
  • 13.4. Insulin Sensitivity Improvement

14. Americas Gliclazide Market

  • 14.1. Introduction
  • 14.2. Argentina
  • 14.3. Brazil
  • 14.4. Canada
  • 14.5. Mexico
  • 14.6. United States

15. Asia-Pacific Gliclazide Market

  • 15.1. Introduction
  • 15.2. Australia
  • 15.3. China
  • 15.4. India
  • 15.5. Indonesia
  • 15.6. Japan
  • 15.7. Malaysia
  • 15.8. Philippines
  • 15.9. Singapore
  • 15.10. South Korea
  • 15.11. Taiwan
  • 15.12. Thailand
  • 15.13. Vietnam

16. Europe, Middle East & Africa Gliclazide Market

  • 16.1. Introduction
  • 16.2. Denmark
  • 16.3. Egypt
  • 16.4. Finland
  • 16.5. France
  • 16.6. Germany
  • 16.7. Israel
  • 16.8. Italy
  • 16.9. Netherlands
  • 16.10. Nigeria
  • 16.11. Norway
  • 16.12. Poland
  • 16.13. Qatar
  • 16.14. Russia
  • 16.15. Saudi Arabia
  • 16.16. South Africa
  • 16.17. Spain
  • 16.18. Sweden
  • 16.19. Switzerland
  • 16.20. Turkey
  • 16.21. United Arab Emirates
  • 16.22. United Kingdom

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2023
  • 17.2. FPNV Positioning Matrix, 2023
  • 17.3. Competitive Scenario Analysis
    • 17.3.1. Endogenex secures eighty-eight million dollars in Series C funding to advance pivotal ReCET study for innovative type 2 diabetes treatment
  • 17.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Anant Pharmaceuticals Pvt. Ltd.
  • 3. Apotex Inc.
  • 4. Biocon
  • 5. Cipla
  • 6. Dr. Reddy's Laboratories
  • 7. Kavya Pharma
  • 8. Kreative Organics
  • 9. Lexicare Pharma Private Limited
  • 10. Lupin Pharmaceuticals
  • 11. Mankind Pharma
  • 12. MANUS AKTTEVA BIOPHARMA LLP
  • 13. Sanify Healthcare
  • 14. Shobha Life Sciences
  • 15. Supra Chemicals
  • 16. Torrent Pharmaceuticals
  • 17. Wellona Pharma
  • 18. Zeelab Pharmacy Private Limited

LIST OF FIGURES

  • FIGURE 1. GLICLAZIDE MARKET RESEARCH PROCESS
  • FIGURE 2. GLICLAZIDE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLICLAZIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLICLAZIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. GLICLAZIDE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. GLICLAZIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLICLAZIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLICLAZIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLICLAZIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLICLAZIDE MARKET DYNAMICS
  • TABLE 7. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLICLAZIDE MARKET SIZE, BY IMMEDIATE RELEASE GLICLAZIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLICLAZIDE MARKET SIZE, BY MODIFIED RELEASE GLICLAZIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLICLAZIDE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLICLAZIDE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLICLAZIDE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLICLAZIDE MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLICLAZIDE MARKET SIZE, BY BLISTER PACKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLICLAZIDE MARKET SIZE, BY BOTTLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLICLAZIDE MARKET SIZE, BY POUCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLICLAZIDE MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLICLAZIDE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GLICLAZIDE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GLICLAZIDE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GLICLAZIDE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GLICLAZIDE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GLICLAZIDE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GLICLAZIDE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GLICLAZIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GLICLAZIDE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GLICLAZIDE MARKET SIZE, BY BLOOD SUGAR CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GLICLAZIDE MARKET SIZE, BY CARDIOVASCULAR BENEFITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GLICLAZIDE MARKET SIZE, BY INSULIN SENSITIVITY IMPROVEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES GLICLAZIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLICLAZIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. POLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. QATAR GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. RUSSIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. SPAIN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. SPAIN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 323. SPAIN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 329. SWEDEN GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. SWEDEN GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 331. SWEDEN GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 337. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 338. SWITZERLAND GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 339. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 345. TURKEY GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. TURKEY GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 347. TURKEY GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 353. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 354. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY PACKAGING, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM GLICLAZIDE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 369. GLICLAZIDE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 370. GLICLAZIDE MARKET, FPNV POSITIONING MATRIX, 2023